DCF (discounted cash flows) evaluation - pretty much industry...

DCF (discounted cash flows) evaluation - pretty much industry standard. Arguably the WACC (weighted average cost of capital) is too high and the outcomes would be higher. Unless there is other news out there, the report clearly engendered some interest today given the stock move. These products will be the future of much of musco-skeletal injury repairs. I suspect Johnson and Johnson will buy the company after the rotator cuff trials come out in in 2nd half 2018, which will be a shame as if the company could bring these products to market successfully itself that share price growth might not be unrealistic. Adoption by the TGA and Orthopaedic surgeons (who naturally fear the cannibalization of their own surgical alternatives) is slow of course...